Tactiva Therapeutics Reports Data Highlighting a Novel Dual CD4/CD8 T Cell Receptor with Potential for Use Against a Broad Range of Cancers

Tactiva Therapeutics today reported on its unique, dual enhanced adoptive cell therapy (DEACT) platform, incorporating its proprietary, engineered CD4/CD8 T cell receptors (TCR) with potential broad utility in cancer immunotherapy, including melanoma and ovarian cancer. A late breaking abstract describing these findings was presented as part of the Annual Meeting of the American Association of Cancer Research (AACR), [PR.com]

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us